Axalbion is a company headquartered in Ireland. Brouky records 2 investors associated with the company.
Axalbion is a clinical-stage pharmaceutical company developing TRPM8 agonists for the treatment of chronic cough and dry eyes, two chronic, common and debilitating disorders, with limited treatment options.
Funding rounds, investor list, risk signals, and comparable startups, all gated to subscribers.